IGF-1 DES
des(1-3) IGF-1
IGF-1 DES (des(1-3) IGF-1) is a gh & growth research compound. Truncated IGF-1 that barely binds IGFBPs — roughly 10x more potent than native IGF-1, with strong local hyperplastic action.
IGF-1 DES quick facts
| Reported research dose | 25mcg-100mcg |
| Route | Subq or IM |
| Frequency | 1x Post-workout · Training days |
| Half-life | ~20-30 min |
| Forms | Injectable |
| Evidence level | Animal + anecdotal |
Potent, short-acting, site-specific. Deep-end tool — blood sugar awareness matters.
How IGF-1 DES works
Truncated IGF-1 that barely binds IGFBPs — roughly 10x more potent than native IGF-1, with strong local hyperplastic action.
Proposed benefits
Researched for lean-mass support, recovery, sleep depth, connective-tissue repair and improved body composition via the GH/IGF-1 axis.
Where to get IGF-1 DES
See vetted vendors for IGF-1 DES →The evidence for IGF-1 DES
Graded by what exists behind each claim.
Human clinical evidence
- No randomized human trials — a research compound with no commercial route to funding one, so the correlative and theoretical tiers are the evidence base rather than a consolation prize.
📊 Correlative data
- DES(1-3)IGF-1 occurs naturally in bovine colostrum and human tissue, and is used widely in cell culture precisely because it is more potent than native IGF-1 in that setting — a laboratory fact rather than a human one.
- Reported use is peri-workout and site-specific. Beyond that the record is self-reported: community dosing logs are real information about tolerability and almost none about efficacy.
🧪 How the mechanism reads
- IGF-1 with the first three amino acids removed. That truncation drops its affinity for the IGF binding proteins by roughly an order of magnitude, so it is far more active per unit and far shorter-lived — the opposite design choice from LR3.
- Short action is the mechanistic argument for peri-workout use and against systemic anabolism, and the same short half-life makes hypoglycemia less likely than with LR3 rather than absent.
Why an empty tier is not a verdict → · What community dosing logs are worth →
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What IGF-1 DES actually does
Des(1-3)IGF-1 is IGF-1 with three amino acids cut off the front. Native IGF-1 is 70 residues; this is 67, missing the N-terminal Gly-Pro-Glu tripeptide. Everything the compound is sold on, and the thing nobody says about it, both come out of that one deletion.
Why those three residues matter: they are the binding-protein handle. In circulation, almost no IGF-1 is free. It is captured by six IGF binding proteins, and the N-terminal region — with the glutamate at position 3 doing much of the work — is a principal contact for IGFBP binding LeRoith 2021. Remove it and affinity for the binding proteins falls dramatically while affinity for the IGF-1 receptor is essentially preserved. The peptide is not more potent at its receptor. It is less captured on the way there. That distinction is the whole page, and "10x more potent" on a product label collapses it.
Now the consequence nobody advertising this mentions. The binding proteins are not obstacles. They are a reservoir and a brake. About 75–80% of circulating IGF-1 rides in a ternary complex with IGFBP-3 and the acid-labile subunit — a ~150 kDa assembly too large to leave the capillary. That complex is what gives IGF-1 a half-life measured in many hours instead of minutes, and it is what stops IGF-1 from acting like insulin LeRoith 2021. Strip the handle and you lose the reservoir, the duration and the brake, all three, in exchange for the potency.
At the receptor, the pharmacology is ordinary and worth stating plainly. IGF-1R is a receptor tyrosine kinase; ligand binding triggers autophosphorylation, IRS-1 recruitment, and PI3K/AKT and MAPK signaling. In muscle that drives protein synthesis and satellite cell activation. IGF-1R also shares roughly 60% homology with the insulin receptor, forms hybrid receptors with it, and at sufficient concentration IGF-1 crosses over onto insulin signaling — which is the mechanism behind the hypoglycemia in the safety section, and it is a receptor fact rather than a warning label.
One more, specific to the local-action claim. The "hyperplastic, acts where you inject it" story requires the peptide to stay near the injection site. A 7.5 kDa protein injected subcutaneously is absorbed largely by lymphatics and reaches the circulation; the free form's short residence is a systemic clearance statement, not a tissue-retention one. Nothing in the IGF literature supports a depot effect for a binding-protein-evading analog — if anything the opposite, since binding proteins are what hold IGF-1 in tissue.
Cell, rodent, human — and where it stops
Step one, the biology of the system: extremely well characterized. Ligands, six binding proteins, the acid-labile subunit, the receptors and the hybrids are all mapped in detail LeRoith 2021. This is one of the best-understood endocrine systems in human physiology.
Step two, in cells and rodents, where des(1-3) earned its reputation. The analog is a standard laboratory reagent precisely because it escapes the binding proteins secreted into culture medium, so it gives a larger response than native IGF-1 at the same molar concentration. That is a true and reproducible observation about cell culture, and it is the origin of the "10x" figure that has been carried onto product pages as though it described a person.
Step three, in humans: there is no des(1-3)IGF-1 clinical literature at all. No pharmacokinetics, no dose-ranging, no safety study, no trial. What exists in humans is full-length recombinant IGF-1 — mecasermin — licensed for severe primary IGF-1 deficiency Fintini 2009, with long-term real-world outcomes now reported through the European registry Ramon-Krauel 2025. Every human statement on this page therefore describes a related but different molecule, and the difference is the exact property this compound is sold for.
What the human rhIGF-1 record actually shows, because it is the closest thing to evidence here. Bang 2023 analyzed hypoglycemia in patients treated with rhIGF-1 in the Eu-IGFD registry and reported its frequency and predictive factors. Hypoglycemia is the dose-limiting toxicity of IGF-1 therapy in practice, it is why mecasermin is dosed with food, and it is a measured clinical fact rather than a theoretical concern.
The obstacles, named one at a time. (1) The potency claim comes from culture medium; a person's binding-protein environment is not culture medium. (2) There is no human PK, so the card's "~20–30 min" is inference from free IGF-1 kinetics, not a measurement of this analog in a person. (3) A 67-residue protein is far harder to make correctly than a short peptide — three disulfide bonds have to form in the right pairing or the molecule is inactive or wrongly active, and no purity certificate reports disulfide connectivity. (4) The literature that exists on the licensed molecule is pediatric growth failure Ramon-Krauel 2025, a population and an endpoint with no relationship to adult muscle.
IGF-1 DES pharmacokinetics — how much of it actually gets in
The card says 20–30 minutes. No one has measured it for this analog in a human, so here is where that number comes from and what it implies.
What degrades it. Not a small-molecule pathway — this is a 7.5 kDa protein, cleared by renal filtration and tubular catabolism plus general proteolysis. The rate-limiting factor is not an enzyme at all: it is whether the molecule is bound. Free IGF-1 has a half-life of roughly 10 minutes; in the binary complex with a binding protein it is on the order of 30–90 minutes; in the ternary complex with IGFBP-3 and the acid-labile subunit it is 12–15 hours LeRoith 2021. A 100-fold range for the same protein, set entirely by what it is riding in. Des(1-3) is engineered to ride in nothing, which places it at the fast end by construction.
The oral barrier does not apply and the route is not optional. A 7.5 kDa disulfide-bonded protein has no meaningful oral bioavailability; gastric acid and pancreatic proteases destroy it and nothing that size crosses the enterocyte intact. Injection is the only route, which is why there is no oral variant of this product to argue about.
The arithmetic, and it is the argument for the dosing pattern people use. A 50 mcg dose is roughly 6.7 nmol; into 5 L of plasma that is about 1.3 nmol/L at complete absorption, against a normal total IGF-1 concentration of roughly 20–30 nmol/L — so the injected material is a small addition to the total pool and a large addition to the free pool, because the free fraction is normally well under 1%. That asymmetry is the entire pharmacology: this compound moves the small unbound compartment, which is the one the receptor sees and the one that also reaches the insulin receptor. With a half-life near 10–20 minutes, the exposure is over inside about an hour, which is why the community protocol is peri-workout and why the "long-acting" framing some vendors use is not consistent with any published IGF kinetics.
What would have to be true, and how you would know it was not
Three predictions. The first is a genuine surprise to most users, and the second is the one that matters for safety.
1. Serum IGF-1 should barely move, and if it does move, something else is in the vial. A standard serum IGF-1 assay measures the total pool, which is overwhelmingly the ternary complex LeRoith 2021. A binding-protein-evading analog does not join that pool and is cleared within the hour, so a correctly manufactured des(1-3)IGF-1 should produce little or no rise in a morning serum IGF-1 drawn the next day. This is the most useful test on the page and it runs backwards from what people expect: a big sustained IGF-1 rise after des(1-3) suggests full-length rhIGF-1, or a growth hormone secretagogue, rather than the labeled product.
2. Glucose is the acute safety measurement, and fasting insulin and HbA1c are the chronic ones. IGF-1 crosses onto insulin signaling at sufficient free concentration, and hypoglycemia is the documented dose-limiting effect of IGF-1 therapy in human practice Bang 2023. Free-fraction-maximizing design plus a fasted injection is the exact combination that produces it. Check glucose with a meter around the first doses; draw fasting insulin and HbA1c at baseline and 8–12 weeks for the longer question.
3. The falsification test for the hypertrophy claim is a measurement, not a mirror. If the local hyperplasia story is right, the effect should be region-specific and should show up as a limb circumference or ultrasound thickness difference between a treated and an untreated side, with training matched. Nobody does the matched-limb version, and without it the compound gets credit for the training block that accompanied it. Add a CMP for renal and hepatic safety, since clearance is renal.
What nobody has tested yet
Four experiments that have never been done, and the first is startling given how long this has been sold.
Nobody has published a single human plasma concentration after a des(1-3)IGF-1 injection. The assay technology is mature Bailes 2021. One subject, one dose, six time points would produce the first human pharmacokinetic data this molecule has, and it would settle whether the card's 20–30 minutes is right.
Nobody has confirmed what is in the vials. Distinguishing des(1-3)IGF-1 from full-length rhIGF-1 is a routine mass-spectrometry problem — the mass difference is that of Gly-Pro-Glu, about 284 Da, which any intact-mass instrument resolves easily. Nobody has surveyed the market, and given the price difference and the manufacturing difficulty, that survey is the highest-value experiment on this page.
Nobody has tested the matched-limb hypothesis. The local hyperplasia claim is directly testable with unilateral dosing and bilateral ultrasound, in a design borrowed straight from the training literature, and it has never been run for any IGF analog.
Nobody has looked at what it does to the doping-control markers. Cowan 2022 established procollagen type III amino-terminal propeptide and IGF-I as the biomarkers of growth hormone administration. Whether a short-acting IGF analog moves the same markers, and for how long, is unstudied — which matters for any tested athlete and is unpublished in either direction.
IGF-1 DES — its own safety story, not its class's
The class block above is written for growth-axis compounds generally. Three things belong to this one.
Hypoglycemia is the documented risk, and this analog is designed to maximize the fraction that causes it. Bang 2023 quantified hypoglycemia in patients on rhIGF-1 and identified predictive factors; the standard clinical mitigation is to dose with food. Des(1-3) raises the free fraction by design, so the same risk arrives faster and at a lower total dose. A fasted injection, and an injection combined with hard training, are the two situations where the risk is highest, and both are common practice.
The manufacturing risk is larger here than for any peptide on this site. IGF-1 requires three disulfide bonds in a specific pairing to fold correctly. A recombinant protein that misfolds is not a weak version of the drug; it is a different molecule, and an unfolded or aggregated protein is also the classic trigger for an immune response. Certificates of analysis report mass and purity by HPLC. Neither of those detects wrong disulfide pairing.
The proliferative question, stated at the right strength. IGF-1R signaling is mitogenic and anti-apoptotic; epidemiology links higher circulating IGF-1 with some cancer incidence, and the licensed product's own labeling reflects caution about active malignancy. None of this is evidence that injected des(1-3)IGF-1 causes cancer, and no such study exists in any species. The honest statement is that the pathway is the one growth-signaling pathway oncology spends most effort trying to inhibit, and nobody has characterized what repeated deliberate stimulation of its free-ligand pool does over years in a healthy person.
What is not a real risk here. Accumulation. With a half-life in the tens of minutes there is no build-up between doses; the exposure profile is a series of spikes, and any long-term effect is a consequence of what those spikes triggered, not of drug that stayed.
Sources read for this page
- LeRoith D, et al. Insulin-like growth factors: Ligands, binding proteins, and receptors. Molecular Metabolism 2021 · PMID 33962049
- Bang P, et al. Frequency and predictive factors of hypoglycemia in patients treated with rhIGF-1: Data from the Eu-IGFD Registry. Journal of Clinical Endocrinology and Metabolism 2023 · PMID 37579214
- Fintini D, et al. Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency. Therapeutics and Clinical Risk Management 2009 · PMID 19707272
- Ramon-Krauel M, et al. Near-adult height outcomes in patients treated with rhIGF-1 for severe growth failure: real-world IGFD Registry data. Journal of Clinical Endocrinology and Metabolism 2025 · PMID 40626687
- Cowan DA, et al. Procollagen type III amino-terminal propeptide and insulin-like growth factor I as biomarkers of growth hormone administration. Drug Testing and Analysis 2022 · PMID 34418311
- Bailes J, Soloviev M. Insulin-Like Growth Factor-1 (IGF-1) and Its Monitoring in Medical Diagnostic and in Sports. Biomolecules 2021 · PMID 33557137
IGF-1 DES — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These inhibit myostatin or activin signaling — the brake on muscle growth. Removing a brake the body installed deliberately is the whole premise, and the predicted problems follow from that.
- Myostatin and activin are not muscle-only signals. The same TGF-β family regulates tendon and connective tissue, and the concern that follows is muscle gaining force capacity faster than tendon adapts — predicting tendon and joint injury rather than muscle injury.
- Activin signaling also has roles in reproduction and inflammation, so systemic inhibition has predicted consequences well beyond the muscle the user is aiming at.
What has actually been reported
- Trials of myostatin-pathway drugs have repeatedly shown the dissociation that matters: muscle mass increases without a proportional increase in strength or function. That result recurs across programs and is the main reason several were discontinued.
- Bimagrumab produced muscle gain and fat loss in trials alongside diarrhea and muscle spasms.
- YK-11 has no human trial data at all. It is frequently described as a myostatin inhibitor on the strength of a single cell-culture study.
How to reduce the risk
Same mechanism as the prediction.
- If tendon lags muscle, the answer is loading tendon deliberately — slow heavy resistance work — and not adding load as fast as the new muscle allows.
- Treat rapid strength gain as a reason to be more conservative with progression, not less.
What it does to your bloodwork
A fact about the assay.
- Liver function, especially for the oral compounds in this group. Creatine kinase if you are getting unusual soreness or spasm.
Don't run this if
- You have a history of tendon injury, or you are progressing loading aggressively already.
The honest unknown
- Almost everything. No compound in this group has established long-term human safety, and the consistent trial finding is that mass gained this way has not translated into function.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
IGF-1 DES — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What IGF-1 DES moves on your bloodwork
Expected direction, not a measured one.
- IGF-1 (Insulin-like Growth Factor 1) — ↑ expected to rise
This is the point. IGF-1 rising is the compound doing its job — it is the stable downstream readout of a GH pulse.
What to do: Test it before you start and again at 6–8 weeks. It is the only number that tells you whether the product was real and the dose was enough. - Growth Hormone, Serum — ✕ unreliable here
A random GH level is close to meaningless here. GH is secreted in pulses during deep sleep and sits undetectable between them, so a daytime draw catches a trough almost every time — including when the compound is working perfectly.
What to do: Do not use GH to judge a secretagogue. Read IGF-1 instead. - Fasting Insulin — ↑ expected to rise
GH is a counter-regulatory hormone: it opposes insulin. Fasting insulin and glucose drifting up is the predicted trade-off, not a surprise.
What to do: Check fasting insulin and HbA1c at baseline and again at 8–12 weeks. This is the marker that decides whether you keep running it. - HbA1c (Hemoglobin A1c) — ↑ expected to rise
Same mechanism, longer window — a slow drift rather than a jump.
What to do: Pair it with fasting insulin; either alone can mislead. - Free T4 (Thyroxine) — ↓ expected to fall
GH accelerates the peripheral conversion of T4 to T3, so free T4 can fall while free T3 holds or rises. Read alone it looks like new hypothyroidism, and it usually isn't.
What to do: Run a full thyroid panel rather than TSH alone before concluding anything.
Everything above follows from one fact: these raise GH and therefore IGF-1. Nothing here needs a trial of the specific molecule.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Needle gauge and injection site
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — IGF-1 DES in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside IGF-1 DES
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| Comprehensive Metabolic Panel (CMP) | Fasting glucose — hypoglycemia risk is the headline with IGF analogs |
| IGF-1 (Insulin-like Growth Factor 1) | Baseline before adding to it |
| Fasting Insulin | The axis being manipulated |
The “Running GH Peptides or MK-677” panel covers these in one order — 9 markers, $132.30 with the discount applied.
Check results you already have → · All 103 markers A–Z
IGF-1 DES — frequently asked questions
What is IGF-1 DES?
IGF-1 DES (des(1-3) IGF-1) is a gh & growth research compound. Truncated IGF-1 that barely binds IGFBPs — roughly 10x more potent than native IGF-1, with strong local hyperplastic action.
Is the full IGF-1 DES protocol on this page?
The reported research dose is on this page, along with how IGF-1 DES works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of IGF-1 DES?
IGF-1 DES has an approximate half-life of ~20-30 min, which is part of what determines how often it's dosed.
What's the evidence behind IGF-1 DES?
Current evidence level: Animal + anecdotal. IGF-1 DES is offered for research purposes only and is not an approved medicine.
What IGF-1 DES is used for
IGF-1 DES appears under 1 goal in the goal router.
Related GH & Growth compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.